Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14132348 | 0.79 | ARG1 (0.35) | ARG1TLR8 | |
| SCHEMBL27348053 | 0.77 | LPO (0.42) | ARG1TLR8 | |
| SCHEMBL27589887 | 0.74 | FDPS (0.50) | — | |
| SCHEMBL309967 | 0.73 | FDPS (0.39) | — | |
| SCHEMBL2698209 | 0.73 | HSP90AA1 (0.42) | — | |
| SCHEMBL16182089 | 0.73 | — | — | |
| SCHEMBL27686570 | 0.71 | FDPS (0.31) | — | |
| SCHEMBL27831516 | 0.70 | SMN1; SMN2 (0.33) | HPSE | |
| SCHEMBL13092480 | 0.69 | TLR8 (0.49) | TLR8 | |
| SCHEMBL27362838 | 0.69 | ALDH1A1 (0.39) | ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002466-A1 | PROCESS FOR THE PREPARATION OF CENOBAMATE ANND INTERMEDIATES THEREOF | METROCHEM API PVT LTD | 2025-01-02 | — | — | US | disclosed |
| WO-2023152711-A1 | PROCESS FOR THE PREPARATION OF CENOBAMATE AND INTERMEDIATES THEREOF | METROCHEM API PVT LTD (IN) | 2023-08-17 | — | — | WO | disclosed |
| CN-101784542-B | Imidazolone derivatives, preparation method and biological application | UNIV RENNES | 2014-04-02 | — | — | CN | disclosed |
| EP-1879873-B1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-10-09 | — | — | EP | disclosed |
| CN-101784542-A | Imidazolone derivatives, preparation method and biological application | UNIV RENNES | 2010-07-21 | — | — | CN | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| US-20060258718-A1 | Neurotherapeutic azole compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258718-A1 | Neurotherapeutic azole compounds | CHRNA10, CHRNA4, CHRNA3 | ARG1 2479/4885TLR8 3032/4885NUDT1 2161/4885 |
| US-20250002466-A1 | PROCESS FOR THE PREPARATION OF CENOBAMATE ANND INTERMEDIATES THEREOF | TALDO1, AURKB, PGD | ARG1 3179/4885TLR8 4737/4885NUDT1 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.